Biogen Inc. (BIIB)
|Net Income (ttm)||2.06B|
|Day's Range||216.61 - 219.65|
|52-Week Range||187.16 - 351.86|
|Price Target||238.94 (+9.8%)|
|Earnings Date||Jul 20, 2022|
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. ... [Read more...]
In 2021, Biogen's revenue was $10.98 billion, a decrease of -18.32% compared to the previous year's $13.44 billion. Earnings were $1.56 billion, a decrease of -61.10%.Financial Statements
According to 40 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is 238.94, which is an increase of 9.82% from the latest price.
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.
EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 ...
TOKYO and CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Eisai Co., Ltd.
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Eryth...
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that The New England Journal of Medicine (NEJM) has published positive results from the cutaneous lupus ery...
Wall Street has heated up in July following June's gloomy market behavior. But if you thought it's too late to act now or even too early to buy, there are undervalued S&P 500 stocks which smartly dictat...
Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
Biogen Inc. BIIB, +1.34% said Tuesdsay that its experimental treatment for a type of amyotrophic lateral sclerosis (ALS), which is often referred to as Lou Gehrig's disease, has been granted Priority Re...
FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for tofersen, an...
BIIB vs. ILMN: Which Stock Is the Better Value Option?
Biogen Inc. (BIIB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biogen Inc (NASDAQ: BIIB) has announced a Q2 2002 revenue of $2.589 billion. GAAP net income was $1.058 billion or $7.24 per diluted share, and non-GAAP net income was $767 million or earnings of $5.25 ...
The second-quarter earnings season is upon us, and the news coming out of several members of Big Pharma could potentially shake up their share prices. Beyond that, several unknowns could impact top-tier...
Biogen delivered a Q2 beat on the top and bottom lines, but a lack of important disclosures is hurting sentiment for BIIB stock. The post Biogen (BIIB) Stock Dips Following Q2 Earnings Report appeared f...
Biogen beats Q2 earnings expectations, stock dips
Yahoo Finance Live anchors Julie Hyman, Brian Sozzi and Brad Smith discuss second-quarter earnings for Biogen.
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The company said earnings are expected to be between $15.25 and $16.75 per share for this year, more than prior expectation of $14.25 to $16.00.
Shares of Biogen Inc. were down 2.8% in premarket trading on Wednesday after the company missed on revenue in the second quarter of the year. Revenue for three of Biogen's top-selling therapies - muscu...
Biogen stock fell early Wednesday after the biotech company reported adjusted profit of $5.25 per share on sales $2.59 billion in the second quarter. The post Biogen Stock Falls Despite Beat-And-Raise Q...
(Reuters) -Biogen Inc on Wednesday posted second-quarter profit that more than doubled, driven by a roughly $1.5-billion gain from the sale of its equity stake in the Samsung Bioepis Joint Venture.
Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on I...